Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Regulatory News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 328.00
Bid: 325.50
Ask: 330.00
Change: 28.00 (9.33%)
Spread: 4.50 (1.382%)
Open: 304.00
High: 350.00
Low: 303.00
Prev. Close: 300.00
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

4 Apr 2017 07:00

RNS Number : 4499B
Oxford Biomedica PLC
04 April 2017
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Oxford BioMedica plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Joy Group Limited

City and country of registered office (if applicable)

Road Town, Tortola, BVI

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

Trade date 03/04/2017 / Value date 05/04/2017

6. Date on which issuer notified (DD/MM/YYYY):

04/04/2017

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

6.9%

Position of previous notification (if

applicable)

N/A

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB0006648157

215,793,548

6.9%

SUBTOTAL 8. A

215,793,548

6.9%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

N/A

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

N/A

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Joy Group Limited

6.9%

Proxy voting

10. Name of the proxy holder

See section 3

11. The number and % of voting rights held

12. The date until which the voting rights will be held

13. Additional informationxvi

Joy Group Limited is a controlled undertaking of The Al Joy 1 Trust, which is a trust registered in Jersey

 

14. Contact name:

Tim Watts

15. Contact telephone number:

01865 783000

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUOARRBRASRUR
Date   Source Headline
6th Jun 20191:08 pmRNSAxovant update on 1st cohort of Sunrise-PD trial
6th Jun 201911:39 amRNSHolding(s) in Company
5th Jun 201912:06 pmRNSHoldings in Company
4th Jun 20195:38 pmRNSHoldings in Company
4th Jun 20199:59 amRNSTotal Voting Rights
3rd Jun 20196:06 pmRNSHolding(s) in Company
3rd Jun 201910:31 amRNSTotal Voting Rights
29th May 20196:19 pmRNSExercise of Subscription Option by Novo Holdings
29th May 20191:06 pmRNSResult of AGM
28th May 20197:00 amRNSStrategic Investment by Novo Holdings A/S
23rd May 20196:04 pmRNSDirector Dealings / Market Share Purchase
2nd May 20192:53 pmRNSLong Term Incentive Plan Option Grant
1st May 201912:52 pmRNSREPLACEMENT: Total Voting Rights
1st May 201911:33 amRNSTotal Voting Rights
30th Apr 20195:38 pmRNSHoldings in Company
30th Apr 20191:35 pmRNSOxford Biomedica to present at the ASGCT
30th Apr 20191:15 pmRNSAxovant doses second cohort of AXO-Lenti-PD
25th Apr 20193:38 pmRNSDirector Dealings / Market Share Purchase
23rd Apr 20191:47 pmRNSDeferred Bonus Plan and LTIP Option Grants
23rd Apr 201911:38 amRNSDirector Dealings / Market Share Transactions
18th Apr 20195:33 pmRNSExercise of warrants
18th Apr 20197:00 amRNSAnnual Report and Accounts & AGM Notification
1st Apr 201911:40 amRNSTotal Voting Rights
26th Mar 201912:57 pmRNSDirector Dealings / Market Share Purchase
26th Mar 20198:25 amRNSJapanese approval of Kymriah® (tisagenlecleucel)
14th Mar 20197:00 amRNSPreliminary Results
12th Mar 20197:00 amRNSOXB announces R&D collaboration with Microsoft
11th Mar 201910:38 amRNSAxovant's update on Phase 2 trial of AXO-Lenti-PD
1st Mar 20199:30 amRNSTotal Voting Rights
25th Feb 201912:23 pmRNSDirector Dealings / Market Share Purchase
8th Feb 20197:00 amRNSNotice of Results
7th Feb 201911:49 amRNSDirector/PDMR Shareholding
7th Feb 20199:22 amRNSUpdate on programmes outlicensed to Sanofi
6th Feb 201911:00 amRNSDirector Dealings / Market Share Transactions
5th Feb 201910:22 amRNSDirector Dealings / Market Share Purchase
1st Feb 201910:00 amRNSTotal Voting Rights
24th Jan 201911:20 amRNSDirector Dealings / Market Share Purchase
3rd Jan 201912:20 pmRNSBlock listing Interim Review
2nd Jan 201910:17 amRNSTotal Voting Rights
21st Dec 20181:16 pmRNSDirector Dealings / Market Share Purchase
6th Dec 20184:11 pmRNSAxovant FDA meeting feedback
3rd Dec 20189:53 amRNSTotal Voting Rights
3rd Dec 20187:00 amRNSLonger term Kymriah efficacy and safety data
23rd Nov 201810:41 amRNSDirector Dealings
23rd Nov 20187:00 amRNSOxford Biomedica form digital framework initiative
9th Nov 20187:00 amRNSBlock listing application
1st Nov 20182:41 pmRNSTotal Voting Rights
25th Oct 20187:00 amRNSAxovant Doses First Patient with AXO-Lenti-PD
22nd Oct 20184:39 pmRNSDirector Dealings / Market Share Purchase
5th Oct 20187:00 amRNSDetails of alliance with Orchard Therapeutics

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.